Literature DB >> 15885452

The influence of dose on the performance of dry powder inhalation systems.

Paul M Young1, Stephen Edge, Daniela Traini, Matthew D Jones, Robert Price, Dina El-Sabawi, Claire Urry, Charlotte Smith.   

Abstract

The relationship between drug/lactose ratio and aerosolisation performance of conventional carrier based formulations was investigated using the twin stage impinger. A dose range of approximately 10-450 microg of drug in a 50 mg lactose carrier formulation was studied. Statistical differences in both the fine particle dose and fine particle fraction were observed across the dosage range (ANOVA, p<0.05). In general, no statistically significant difference (Fishers Pairwise, p<0.05) in fine particle dose was observed between drug levels of approximately 10 microg and 135 microg, whereas a linear decrease in fine particle fraction was observed across the same drug level range (R2=0.977). Increasing the dose from approximately 135 microg to 450 microg resulted in a statistically significant increase in both fine particle dose and fraction (ANOVA p<0.05). Such observations may be attributed to the occupation of 'active' carrier sites by drug particles at low drug concentration, since the quantity of drug particles liberated from the carrier during aerosolisation remains constant at the lower dosing regimes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885452     DOI: 10.1016/j.ijpharm.2005.02.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  15 in total

Review 1.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

2.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

3.  The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.

Authors:  Susan Hoe; Daniela Traini; Hak-Kim Chan; Paul M Young
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

4.  An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.

Authors:  Hanne Kinnunen; Gerald Hebbink; Harry Peters; Jagdeep Shur; Robert Price
Journal:  AAPS PharmSciTech       Date:  2014-04-23       Impact factor: 3.246

5.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

6.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

7.  Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.

Authors:  Pardis Kalantarian; Abdolhosein Rouholamini Najafabadi; Ismaeil Haririan; Alireza Vatanara; Yadollah Yamini; Majid Darabi; Kambiz Gilani
Journal:  Int J Nanomedicine       Date:  2010-10-05

8.  Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.

Authors:  Ping Du; Ju Du; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-06-25       Impact factor: 3.246

9.  Lactose composite carriers for respiratory delivery.

Authors:  Paul M Young; Philip Kwok; Handoko Adi; Hak-Kim Chan; Daniela Traini
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

10.  Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.

Authors:  Paul M Young; Adrian Sung; Daniela Traini; Philip Kwok; Herbert Chiou; Hak-Kim Chan
Journal:  Pharm Res       Date:  2007-03-22       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.